UBS analyst Kevin Caliendo lowered the firm’s price target on UnitedHealth to $550 from $590 and keeps a Neutral rating on the shares. UnitedHealth’s Q4 results were broadly positive, but thinks shares will remain range-bound until there is more clarity on the final RADV ruling and the advanced rate notice and how they impact Medicare Advantage, Caliendo tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on UNH:
- UnitedHealth price target raised to $590 from $575 at Loop Capital
- UNH Little Changed after Beating Earnings and Reaffirming Guidance
- UnitedHealth expects to have more than 750 community pharmacies by 2023E
- UnitedHealth backs FY23 adjusted EPS view $24.40-$24.90, consensus $24.94
- UnitedHealth reports Q4 adjusted EPS $5.34, consensus $5.17